PT-141 Peptide

## What it is PT-141 (bremelanotide, brand name Vyleesi) is a synthetic cyclic 7-amino-acid peptide and melanocortin receptor agonist with preference for the MC4 receptor. It was developed by Palatin Technologies originally as an analog of alpha-MSH, with an early clinical program targeting male erectile dysfunction. The FDA approved Vyleesi for hypoactive sexual desire disorder (HSDD) in pre-menopausal women in June 2019 based on the RECONNECT-1 and RECONNECT-2 phase 3 trials. The compound's distinguishing feature is its mechanism: unlike PDE5 inhibitors such as sildenafil and tadalafil, which target peripheral vascular smooth muscle in the penis, bremelanotide engages central MC4R circuits in the hypothalamus that regulate sexual motivation and desire. This makes it pharmacologically suitable for desire disorders rather than purely erectile mechanics. Users fall into three groups: pre-menopausal women with HSDD using FDA-approved Vyleesi as labeled, men using off-label compounded versions for erectile dysfunction (particularly PDE5 non-responders), and a smaller cohort using it for libido enhancement outside any clinical indication. Compounded versions are research-use-only grey market and not FDA-approved. ## Mechanism of action Bremelanotide is a synthetic agonist of melanocortin receptors with preference for MC4R, which is expressed in hypothalamic and limbic circuits regulating sexual motivation. MC4R activation in these circuits modulates downstream dopaminergic signaling in the medial preoptic area and other regions central to sexual desire. The pathway is mechanistically distinct from peripheral PDE5-mediated vasodilation, which is why the two classes are sometimes combined in non-responders without obvious pharmacologic conflict. Minor activity at MC1R explains the hyperpigmentation observed with repeated dosing, and MC3R involvement may contribute to the cardiovascular effects (transient blood pressure elevation). Plasma half-life is approximately 2.7 hours, but the sexual-desire window typically extends to around 6 hours after a single dose, reflecting downstream signaling persistence beyond plasma exposure. Onset after subcutaneous administration is roughly 45 minutes, peak effect occurs around 1 to 2 hours, and the pharmacodynamic window for sexual activity is recommended within 6 hours of dosing per the Vyleesi label. ## Evidence base The RECONNECT-1 and RECONNECT-2 phase 3 trials (combined n=1247) randomized pre-menopausal women with HSDD to bremelanotide 1.75 mg subcutaneous as needed versus placebo over 24 weeks. Both trials reported statistically significant improvements in the Female Sexual Function Index desire domain (FSFI-D) and reductions in sexual distress measured by the Female Sexual Distress Scale (FSDS-DAO Item 13). Effect sizes were moderate in clinical terms, with responder rates roughly 25% on bremelanotide versus 17% on placebo for the predefined desire-improvement threshold. A 52-week open-label extension showed sustained efficacy with continued use and no major cardiovascular MACE signal, though transient blood pressure elevation of approximately 6 mmHg systolic was observed per dose. Hyperpigmentation occurred in roughly 1% of repeated users, typically focal on gums, face, or breasts, and was reversible on discontinuation. Male erectile dysfunction evidence is older and weaker. Phase 2 trials in PDE5-naive and PDE5-non-responder men reported significant International Index of Erectile Function (IIEF) score improvements versus placebo across roughly 600 participants. Diamond 2004 and Rosen 2004 are the most-cited reports. Palatin's original male program was not advanced to FDA submission, and male use today is exclusively off-label. The transient blood pressure rise observed in trials, plus a single signal of cardiovascular events in the integrated safety database, drove the FDA to restrict approved use to pre-menopausal women without uncontrolled hypertension or established cardiovascular disease. Long-term cardiovascular outcome data beyond the 52-week extension is limited. ## Dosage and administration The FDA-approved Vyleesi label specifies 1.75 mg subcutaneous as needed, no more than once per 24 hours and no more than 8 doses per month. The dose is administered approximately 45 minutes before anticipated sexual activity. The pre-filled autoinjector simplifies self-administration and rotates between abdomen and thigh. Off-label male ED dosing in compounded forms typically uses 1 to 2 mg subcutaneously, dosed similarly on demand 45 to 60 minutes before activity. There is no validated dosing schedule for male use because the male program never reached FDA submission. Compounded vials are typically 10 mg lyophilized powder reconstituted with 1 mL bacteriostatic water giving 10 mg/mL. A 1 mg dose draws 10 units on a U100 insulin syringe; a 1.75 mg dose draws roughly 18 units. Reference the existing typicalDoseMg of 1.75 (matching the Vyleesi label) and the on-demand frequency. Bremelanotide is not used continuously and is not cycled. The on-demand pharmacology and the cumulative cardiovascular exposure constraints make daily dosing inappropriate. ## Side effects and safety Nausea is the dominant adverse effect, occurring in roughly 40% of users in the Vyleesi trials. Most cases are transient (resolve within 2 hours) and diminish across repeated doses. Anti-emetics are sometimes co-administered. Other common effects include flushing, headache, injection-site reactions, and focal hyperpigmentation in approximately 1% of repeated users. The transient blood pressure rise of approximately 6 mmHg systolic per dose is the safety driver behind the FDA's exclusion of patients with uncontrolled hypertension or established cardiovascular disease. Contraindications per the Vyleesi label include uncontrolled hypertension, established cardiovascular disease, pregnancy, and concurrent oral naltrexone use (bremelanotide significantly reduces oral naltrexone exposure, so co-administration is contraindicated for patients on naltrexone for alcohol or opioid use disorder). No documented adverse interaction with PDE5 inhibitors exists; the mechanisms are non-overlapping. Antihypertensive effectiveness can be partially offset by the per-dose BP rise. The compound is not on the WADA Prohibited List for the FDA-approved Vyleesi formulation. ## Practical notes Vyleesi autoinjectors ship pre-filled and require no reconstitution; store at room temperature and protect from light per labeling. Compounded vials are reconstituted with bacteriostatic water and refrigerated; sterility and potency vary by pharmacy and the FDA-approved Vyleesi remains the gold standard for documented quality. Expect onset around 45 minutes after subcutaneous dosing, peak around 1 to 2 hours, and a useful sexual-activity window of approximately 6 hours. Nausea typically peaks early and resolves before the desire window opens; some users find that pre-dosing with food, water, or an OTC anti-emetic improves tolerability. The trial data support modest but real efficacy in HSDD; off-label male use rests on older phase 2 data with no FDA validation. Set realistic expectations: this is a desire-domain pharmacology, not a guaranteed-arousal switch, and the responder rate in trials was meaningful but not universal.